Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + azacitidine + chidamide for angioimmunoblastic T-cell lymphoma
ChiCTR2300075418Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, azacitidine and tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2023; status: recruiting.
02
Drugs
mitoxantrone-liposomeazacitidinetucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on ChiCTR2300075418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075418.